Administration of Exendin-4 but not CCK alters lick responses and trial initiation to sucrose and intralipid during brief-access tests.
Sign Up to like & getrecommendations! Published in 2022 at "Chemical senses"
DOI: 10.1093/chemse/bjac004
Abstract: Administration of cholecystokinin (CCK) or the glucagon-like peptide 1 (GLP-1) receptor agonist Exendin-4 (Ex-4) reduces food intake. Findings in the literature suggest CCK reduces intake primarily as a satiety signal whereas GLP-1 may play a… read more here.
Keywords: administration; sucrose intralipid; lick responses; brief access ... See more keywords